{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:19:48Z","timestamp":1791883188270,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jaac.2013.04.018","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T21:02:33Z","timestamp":1370466153000},"page":"689-698.e3","source":"Crossref","is-referenced-by-count":26,"title":["Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes"],"prefix":"10.1016","volume":"52","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Mankoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2013.04.018_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/14737175.4.1.53","article-title":"Pharmacologic treatment of adolescent and child schizophrenia","volume":"4","author":"Young","year":"2004","journal-title":"Expert Rev Neurotherapeut"},{"key":"10.1016\/j.jaac.2013.04.018_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/YCO.0b013e32833b027e","article-title":"Treatment of early-onset schizophrenia","volume":"23","author":"Mattai","year":"2010","journal-title":"Curr Opin Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.jaac.2013.04.018_bib3","first-page":"21","article-title":"Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders","volume":"69","author":"Sikich","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib4","unstructured":"American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. In press."},{"key":"10.1016\/j.jaac.2013.04.018_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.bp.107.040410","article-title":"Cognitive markers of short-term clinical outcome in first-episode psychosis","volume":"193","author":"Bodnar","year":"2008","journal-title":"Br J\u00a0Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/11314280-000000000-00000","article-title":"Antipsychotic drugs for first-episode schizophrenia: a comparative review","volume":"23","author":"Salimi","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaac.2013.04.018_bib7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2013.04.018_bib9","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1176\/appi.ajp.160.11.2063","article-title":"Early prediction of antipsychotic response in schizophrenia","volume":"160","author":"Correll","year":"2003","journal-title":"Am J\u00a0Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended","volume":"57","author":"Leucht","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","article-title":"Early prediction of antipsychotic nonresponse among patients with schizophrenia","volume":"68","author":"Leucht","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to\u00a0antipsychotic drug therapy as a clinical marker of subsequent\u00a0response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jaac.2013.04.018_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/01.jcp.0000246211.95905.8c","article-title":"Optimizing early prediction for antipsychotic response in schizophrenia","volume":"26","author":"Chang","year":"2006","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/schbul\/sbm134","article-title":"Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia","volume":"34","author":"Ascher-Svanum","year":"2008","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2013.04.018_bib15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.4088\/JCP.v68n1008","article-title":"Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine","volume":"68","author":"Lin","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4088\/JCP.11r07064","article-title":"Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics","volume":"72","author":"Correll","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":"Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2013.04.018_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A\u00a0pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jaac.2013.04.018_bib20","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.jaac.2013.04.018_bib22","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2013.04.018_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib26","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"issue":"suppl 19","key":"10.1016\/j.jaac.2013.04.018_bib28","first-page":"6","article-title":"The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice","volume":"64","author":"Stahl","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4088\/PCC.v07n0602","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"suppl 2","key":"10.1016\/j.jaac.2013.04.018_bib30","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4088\/JCP.10r06264yel","article-title":"Past and present progress in the pharmacologic treatment of schizophrenia","volume":"71","author":"Kane","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jaac.2013.04.018_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","article-title":"Characterization of aripiprazole partial agonist activity at human dopamine D receptors","volume":"597","author":"Tadori","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2003.10.025","article-title":"In\u00a0vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function","volume":"483","author":"Jordan","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2009.1152","article-title":"FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse","volume":"302","author":"Kuehn","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2013.04.018_bib37","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A\u00a0multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib38","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.jaac.2013.04.018_bib39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data","volume":"36","author":"Kaufman","year":"1997","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jaac.2013.04.018_bib41","series-title":"Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2013.04.018_bib42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","article-title":"A\u00a0Children\u2019s Global Assessment Scale (CGAS)","volume":"40","author":"Shaffer","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.chi.0000198590.38325.81","article-title":"Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): reliability and validity","volume":"45","author":"Endicott","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jaac.2013.04.018_bib45","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A\u00a0rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib46","series-title":"US Department of Health Education and Welfare. ECDEU Assessment Manual for Psychopharmacology","article-title":"Abnormal Involuntary Movement Scale (AIMS)","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2013.04.018_bib47","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jaac.2013.04.018_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/YCO.0b013e32835dcc2a","article-title":"A Rational, Evidence Informed Approach to Psychopharmacology for Adolescents with Early Onset, First Episode Psychoses","volume":"26","author":"Schimmelmann","year":"2013","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib50","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.10m06349","article-title":"Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?","volume":"72","author":"Gallego","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","article-title":"Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?","volume":"30","author":"Derks","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.04.018_bib52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1176\/appi.ajp.163.4.743","article-title":"Time course for antipsychotic treatment response in first-episode schizophrenia","volume":"163","author":"Emsley","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.04.018_bib53","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4088\/JCP.v67n1106","article-title":"Remission in first-episode psychosis: predictor variables and symptom improvement patterns","volume":"67","author":"Emsley","year":"2006","journal-title":"J\u00a0Clin Psychiatry"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856713003018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856713003018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T19:23:51Z","timestamp":1563132231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856713003018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0890856713003018"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2013.04.018","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}